Matthew Gall - 07 Mar 2024 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role
Chief Financial Officer
Signature
/s/ Adi Osovsky, as Attorney-in-Fact
Issuer symbol
ITOS
Transactions as of
07 Mar 2024
Net transactions value
$0
Form type
4
Filing time
08 Mar 2024, 20:01:39 UTC
Previous filing
07 Dec 2023
Next filing
19 Nov 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITOS Stock Option (Right to Buy) Award $0 +163,200 $0.000000 163,200 07 Mar 2024 Common Stock 163,200 $11.58 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option shall vest over four years, with 25% vesting on March 7, 2025 and thereafter in equal monthly installments over the next 36 months, subject to the reporting person's continued service to the Issuer.